Clinical feasibility of personalized peptide vaccination for metastatic breast cancer patients
Project/Area Number |
23591914
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
General surgery
|
Research Institution | Kurume University |
Principal Investigator |
TOH Uhi 久留米大学, 医学部, 准教授 (60268901)
|
Co-Investigator(Kenkyū-buntansha) |
KOMATSU Nobukazu 久留米大学, 医学部, 講師 (50343687)
関 直子 久留米大学, 医学部, 講師 (40226634)
|
Co-Investigator(Renkei-kenkyūsha) |
SEKI Naoko 久留米大学, 医学部, 講師 (40226634)
|
Project Period (FY) |
2011-04-28 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2011: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
|
Keywords | 乳がん / がんペプチドワクチン / ペプチドワクチン / がんペプチドワクチン / がん免疫療法 / 乳癌 / 癌免疫療法 / ペプチドワクチン療法 |
Outline of Final Research Achievements |
Personalized peptide vaccination (PPV) therapy has been developed in Kurume University for various solid cancers, in which vaccines are selected from 31 different peptides before vaccination. In this study, we conducted a phase II trial for metastatic recurrent breast cancer (mrBC) patients to investigate the feasibility of PPV. 79 patients with mrBC who had failed standard chemo- and/or endocrine therapy were enrolled. Two to four HLA-matched peptides were selected and were subcutaneously administered. Cytotoxic T lymphocyte (CTL) and IgG responses were measured and immune boosting was observed irrespectively with mrBC subtypes. No severe adverse events were observed. Response was 3 CR and 6 PR. The median progression-free survival time and median overall survival time were 7.5 and 15.9 months. PPV could be feasible for mrBC patients and the combination of chemo- or endocrine therapy might be a novel therapeutic strategy that predominantly targets the tumor-associated antigens.
|
Report
(5 results)
Research Products
(62 results)
-
-
[Journal Article] Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes.2014
Author(s)
Oba MS, Imoto S, Toh U, Wada N, Kawada M, Kitada M, Masuda N, Taguchi T, Minami S, Jinno H, Sakamoto J, Morita S; Japanese Society for Sentinel Node Navigation Surgery.
-
Journal Title
Jpn J Clin Oncol.
Volume: 44
Issue: 9
Pages: 876-879
DOI
Related Report
Peer Reviewed
-
[Journal Article] Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients.2014
Author(s)
Takahashi R, Toh U, Iwakuma N, Takenaka M, Otsuka H, Furukawa M, Fujii T, Seki N, Kawahara A, Kage M, Matsueda S, Akagi Y, Yamada A, Itoh K, Sasada T.
-
Journal Title
Breast Cancer Res.
Volume: 16
Issue: 4
Pages: 00-00
DOI
Related Report
Peer Reviewed / Open Access
-
[Journal Article] Moleculary-Targeted Therapeutic Strategies for Breast Cancer Focusing on HER”-Targeted Therapy,mTOR Inhibitor and Antiangiogenic Therapy2014
Author(s)
Teruhiko Fujii,Keisuke Miwa,Tomoyuki Ushijima,Mototsugu Matsunaga,Masaru Fukahori,Kotaro Yuge,Uhi Toh,Nobutaka Iwakuma,Ryuji Takahashi,Hiroki Takahashi,Miki Takenaka,Mai Mishima,Yoshito Akagi,Masayoshi Kage,Shino Nakagawa,Maki Tanaka
-
Journal Title
Frontiers in Anti-Cancer Drug Discovery
Volume: 4
Pages: 157-228
Related Report
Peer Reviewed / Open Access
-
[Journal Article] FOXP3 expression in tumor cells and tumor-infiltrating lymphocytes is associated with breast cancer prognosis.2013
Author(s)
Takenaka M, Seki N, Toh U, Hattori S, Kawahara A, Yamaguchi T, Koura K, Takahashi R, Otsuka H, Takahashi H, Iwakuma N, Nakagawa S, Fujii T, Sasada T, Yamaguchi R, Yano H, Shirouzu K, Kage M
-
Journal Title
Mol Clin Oncol.
Volume: 1(4)
Pages: 625-632
Related Report
Peer Reviewed
-
[Journal Article] Treatment outcome in patients with stage III breast cancer treated with neoadjuvant chemotherapy2013
Author(s)
Takahashi R, Toh U, Iwakuma N, Mishima M, Fujii T, Takenaka M, Koura K, Seki N, Kawahara A, Kage M, Ogo E, Shirouzu K.
-
Journal Title
Exp Ther Med.
Volume: 6 (5)
Pages: 1089-1095
Related Report
Peer Reviewed
-
-
-
[Journal Article] Usefulness of endoscopic breast-conserving surgery for breast cancer.2013
Author(s)
Takahashi H, Fujii T, Nakagawa S, Inoue Y, Akashi M, Toh U, Iwakuma N, Takahashi R, Takenaka M, Fukuma E, Shirouzu K
-
Journal Title
Related Report
Peer Reviewed
-
-
[Journal Article] Tricin inhibits proliferation of human hepatic stellate cells in vitro by blocking tyrosine phosphorylation of PDGF receptor and its signaling pathways2012
Author(s)
N Seki, U Toh, K Kawaguchi, M Ninomiya, M Koketsu, K Watanabe, M Aoki, T Fujii, A Nakamura, Y Akagi, J Kusukawa, M Kage, K Shirouzu and H Yamana
-
Journal Title
J Cell Biochem
Volume: (in press)
Issue: 7
Pages: 2346-55
DOI
Related Report
Peer Reviewed
-
-
-
-
[Journal Article] Giant malignant phyllodes tumor: a case report.2011
Author(s)
Takenaka M, Toh U, Otsuka H, Takahashi H, Iwakuma N, Nakagawa S, Fujii T, Yamaguchi R, Yano H, Shirouzu K, Kage M
-
Journal Title
Kurume Med J.
Volume: 58(2)
Pages: 67-72
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Safety and immunologic efficacy of personalized multiple HLA class I-restricted peptide vaccines for berast cancer patients in the adjuvant setting2014
Author(s)
U.Toh,N.Iwakuma,M.Mishima,M.Takenaka,R.Takahashi,M.Furukawa,T.Fujii,E.Ogo,S.Nakagawa,M.Tanaka,T.Sasada,K.Itoh,Y.Akagi
Organizer
2014 ASCO Annual Meeting
Place of Presentation
Chicago, USA
Year and Date
2014-05-30 – 2014-06-03
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Personalized peptide vaccines in combination with conventional chemo- or endocrine therapy for metastatic breast cancer: A single-arm phase II study2013
Author(s)
Toh U, Iwakuma N, Mishima M, Takenaka M, Takahashi R, Koura K, Fujii T, Nakagawa S, Ogo E, Tanaka M, Sasada T, Itoh K, Shirouzu K
Organizer
36th San Antonio Breast Cancer Symposium 2013
Place of Presentation
San Antonio, USA
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-